uniQure Shares Plunge Following FDA Rejection of Gene Therapy Approval Pathway

Posted on by

TLDR

  • Shares of uniQure plummeted approximately 45% following the FDA’s rejection of its proposed approval route for AMT-130.

  • The regulatory agency stated that data from early and mid-stage trials were inadequate to back a marketing submission.

  • Before any possible approval submission, the FDA advised conducting a new randomized, controlled clinical trial.

  • uniQure aims to seek another meeting with the FDA in the second quarter of 2026 to deliberate on Phase III trial design.

  • This regulatory hurdle may postpone schedules for the Huntington’s disease gene therapy initiative.

uniQure (QURE) shares experienced a significant drop after the U.S. Food and Drug Administration turned down its suggested approval pathway for AMT-130. This regulatory news prompted a sharp fall in the stock during early market activity.

QURE Stock Card

According to the FDA, information from Phase I/II trials was not enough to justify a marketing application. The agency determined that comparisons made with external control groups failed to satisfy the standards for primary proof of efficacy.

This response came after a Type A meeting conducted on January 30. The final minutes from that meeting solidified the regulator’s stance on the proposed submission route.

The FDA’s recommendation is for uniQure to carry out a prospective, randomized, double-blind study. This proposed trial would incorporate a sham surgery control arm to produce more substantial evidence.

UniQure stated it plans to maintain discussions with the FDA concerning the development of AMT-130. The company’s intention is to ask for a Type B meeting in Q2 2026 to talk about the design of future trials.

Regulatory Setback and Development Timeline

The FDA’s ruling signifies a postponement for the company’s development schedule. UniQure had aimed to pursue marketing authorization for AMT-130 in the beginning of 2026.

This gene therapy candidate is intended to treat Huntington’s disease, an inherited neurological condition that leads to the gradual breakdown of nerve cells in the brain.

Presently, there are no approved therapies that can slow the disease’s advancement. UniQure had been optimistic that its early and mid-phase data would be enough for a regulatory application.

Earlier study outcomes indicated a decrease in disease progression over three years, as measured by clinical scales. However, the FDA maintained that more data from controlled studies is necessary.

Launching a new randomized trial would demand more time and investment. This has the potential to delay any future regulatory filing and the subsequent product launch.

Next Steps and Company Response

UniQure announced it will persist in working with regulators to decide on the subsequent steps in development. Company leadership indicated that talks will center on the possible design and prerequisites for a Phase III trial.

The firm expressed its belief that the current data justifies ongoing conversation with regulatory authorities. It also pointed to the lasting effects of outcomes seen in prior studies.

Analysts observed that executing a new controlled study would lengthen the development process. There may also be extra trial expenses incurred prior to applying for approval.

The company is scheduled to ask for a subsequent meeting with the FDA in Q2 2026. Conversations are anticipated to concentrate on routes to move AMT-130 forward toward a potential future application.

UniQure affirmed its continued dedication to progressing the gene therapy program in spite of the regulatory obstacle. More information is likely to be shared after further discussions with regulators later this year.